Sartorius Stedim Biotech: RBC starts monitoring as buyer

(CercleFinance.com) - Last night, RBC initiated an 'outperform' rating on Sartorius Stedim Biotech, with a target price of E270.


In a note, the Canadian broker considers that the underperformance of the biopharmaceutical equipment specialist is at odds with the company's fundamental recovery.

Sartorius Stedim Biotech's market shares resisted well during the Covid period and have since recovered, in line with those of its peers, the broker comments.

And yet, its share price has significantly underperformed those of its peers, due to downward revisions of its targets, which constitutes an opportunity for investors, it observes.

The professional believes that the company benefits from a 'solid positioning' in an 'attractive' market, that of the supply of materials for the manufacture of biological products and advanced therapies, such as gene therapies.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.